Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-28.3%-28.2%-23.4%-29.4%
Return on assets-26.8%-26.9%+6.3pp-22.6%-28%
Return on invested capital-38.2%-36.1%-39.5%-45.3%
Liquidity
Current ratio27.1×-3.9×26.2×-9.2×36.4×-9.5×22.7×-19.3×31×
Quick ratio27.1×-3.9×26.2×-9.2×36.4×-9.5×22.7×-19.3×31×
Cash ratio4.4×-1.8×2.8×-3.7×17.6×+12.0×4.6×-9.0×6.1×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Per Share
Book value per share$9.98+23.2%$12.45-15.5%$13.49+45.5%$7.43-76.5%$8.11+142%
Valuation
Market capitalization$1.5B+309%$1.45B+123%$1.37B+82.8%$451.84M-46.9%$366.06M
Enterprise value$1.43B+352%$1.4B+137%$1.13B+58.8%$408.64M-45.0%$316.3M
Price / book3.2×+1.9×+0.9×2.7×+0.4×1.7×-0.8×1.3×
Free cash flow yield-5.4%+13.5pp-6.1%+4.3pp-5.7%+2.9pp-17%-10.7pp-18.9%
Earnings yield-7.2%+14.6pp-7.7%+4.4pp-7.1%+2.5pp-19.5%-12.1pp-21.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Rapport Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.